SYMBIOTIX BIOTHERAPIES
Symbiotix Biotherapies is a provider of a novel class of molecular therapeutics intended to develop molecules.The company's novel class of molecular therapeutics include a novel class of Treg-modulating therapeutics based on molecules derived from the human microbiom, enabling patients access first-in-class oral agents that improves their lives and helps them to treat themselves of inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases.
SYMBIOTIX BIOTHERAPIES
Social Links:
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2009-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.symbiotix-bio.com
Total Employee:
1+
Status:
Active
Contact:
(617) 535-3196
Email Addresses:
[email protected]
Total Funding:
9.3 M USD
Technology used in webpage:
IPv6 Google Maps GStatic Google Static Content Google Maps API Cloudflare Hosting Cloudflare DNS
Similar Organizations
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Gyros
Gyros is specialized in the production of automated micro-immunoassays for therapeutic protein development.
Optel Group
Optel Group is a provider of traceability systems for the pharmaceutical and medical device industries.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Current Employees Featured
Founder
Investors List
Kairos Ventures
Kairos Ventures investment in Venture Round - Symbiotix Biotherapies
Official Site Inspections
http://www.symbiotix-bio.com
- Host name: 172.67.170.197
- IP address: 172.67.170.197
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Symbiotix Biotherapies" on Search Engine
Symbiotix Biotherapies Company Profile 2024: …
Symbiotix Biotherapies Overview. Update this profile. Year Founded. 2009. Status. Out of Business. Latest Deal Type. Out of Business. General Information. Description. Developer of a novel class of molecular …See details»
Symbiotix Biotherapies Receives $5 Million in Institutional …
Nov 1, 2017 Symbiotix Biotherapies, Inc. (“Symbiotix”), a pioneering microbiome company developing novel molecular therapeutics based on the human microbiome, …See details»
Symbiotix Biotherapies Receives $5 Million in Institutional
Nov 1, 2017 BOSTON-- ( BUSINESS WIRE )-- Symbiotix Biotherapies, Inc. (“Symbiotix”), a pioneering microbiome company developing novel molecular …See details»
Symbiotix Biotherapies Announces Process Development
Jan 3, 2018 BOSTON--(BUSINESS WIRE)-- Symbiotix Biotherapies, Inc. (“Symbiotix”), a pioneering venture-backed microbiome company developing novel molecular …See details»
SYMBIOTIX BIOTHERAPIES, INC. | VentureRadar
Based on this breakthrough research, the company is advancing a first-in-class approach to improve the treatment of serious lower gastrointestinal (GI) diseases as well as mitigate …See details»
Symbiotix Biotherapies Announces License …
March 21, 2018 Microbiome Times Pharma & Human Health. Symbiotix Biotherapies, Inc. (“Symbiotix”), a pioneering venture-backed microbiome company developing novel molecular therapeutics based on the human …See details»
Symbiotix Biotherapies Announces License Agreement with
Mar 21, 2018 BOSTON-- ( BUSINESS WIRE )-- Symbiotix Biotherapies, Inc. (“Symbiotix”), a pioneering venture-backed microbiome company developing novel …See details»
Symbiotix Biotherapies Announces License Agreement with …
Mar 21, 2018 BOSTON-- ( BUSINESS WIRE )-- Symbiotix Biotherapies, Inc. (“Symbiotix”), a pioneering venture-backed microbiome company developing novel …See details»
Symbiotix Biotherapies Announces Process Development
Jan 3, 2018 Symbiotix Biotherapies, Inc. (“Symbiotix”), a pioneering venture-backed microbiome company developing novel molecular therapeutics based on the human …See details»
Symbiotix Biotherapies Announces Process Development
Jan 3, 2018 BOSTON-- ( BUSINESS WIRE )-- Symbiotix Biotherapies, Inc. (“Symbiotix”), a pioneering venture-backed microbiome company developing novel …See details»
Symbiotix Biotherapies - Funding, Financials, Valuation & Investors
$9.3M. in funding over 3 rounds. Their latest funding was raised on Nov 1, 2017 from a Venture - Series Unknown round. Symbiotix Biotherapies is funded by Kairos …See details»
Symbiotix Biotherapies Expands Microbiome Therapeutic IP …
Apr 3, 2018 Choate recently represented Symbiotix Biotherapies, Inc. (Symbiotix), a pioneering venture-backed biotechnology company developing novel molecular …See details»
Symbiotix Biotherapies - Updates, News, Events, Signals & Triggers
Nov 1, 2017 Funding Round • Jun 1, 2015. Symbiotix Biotherapies raised $2,300,000 / Grant. Discover more funding rounds. Unlock even more features with Crunchbase Pro. …See details»
SYMBIOTIX
Symbiotix was founded in October 1998 and joined Havas Health & You in 2015, extending our global reach and bringing the best in innovation to medical communications. Learn …See details»
Symbiotix Biotherapies, Inc. Asset Profile | Preqin
Founded in 2009 and based in Massachusetts, US, Symbiotix Biotherapies, Inc. is a bio pharmaceutical company that develops molecular therapeutics derived from human microbiome-based molecules. Current Investors. Kairos Ventures. Request a demo to show more. Primary Industry. Pharmaceuticals. Sub Industries. Pharmaceutical Research & …See details»
Symbiotix Biotherapies Announces Issuance Of First ... - BioSpace
Feb 16, 2017 BOSTON-- ( BUSINESS WIRE )--Symbiotix Biotherapies, Inc. (“Symbiotix”), a pioneering microbiome company developing novel molecular …See details»
Symbiotix Biotherapies Announces $2.0 Million Award From …
Sep 21, 2016 BOSTON-- ( BUSINESS WIRE )--Symbiotix Biotherapies, Inc. (“Symbiotix”) today announced that the company was awarded a $2.0 million Phase II …See details»
Symbiotix Biotherapies Announces $2.3 Million Award from NIH's …
BOSTON, June 1, 2015 /PRNewswire/ -- Symbiotix Biotherapies, Inc. ("Symbiotix") today announced that it was awarded a $2.3 million Phase 2 Small Business Technology …See details»
SYMBIOTIX BIOTHERAPIES, INC. | VentureRadar
Symbiotix Biotherapies, Inc. is developing a novel class of molecular therapeutics based on molecules derived from the human microbiome. Emerging... ... Find out more about SYMBIOTIX BIOTHERAPIES, INC., Microbiome and Microbiome and Bacteriome.See details»
SYMB-104: Drug Targets, Indications, Patents - Synapse
Sep 3, 2023 Now, its global highest R&D status is Preclinical, Mechanism: TCR agonists(T-cell receptor agonists), Therapeutic Areas: Immune System …See details»